LP
SYRS

LMR Partners’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

LMR Partners’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,738
Closed -$26K – 1323
2022
Q2 		$26K Buy
+2,738
New +$25.6K ﹤0.01% 1218

Other funds holding SYRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

LMR Partners's SYRS Position: Q3 2022 in Review

LMR Partners sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2022, closing a stake of 2,738 shares — an estimated $26K sold.

LMR Partners first reported a position in SYRS in Q2 2022 and held it in 1 quarter. The position peaked at $26K in Q2 2022. 53 funds tracked by Wall St. Rank hold SYRS as of Q3 2022.

  • LMR Partners reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • LMR Partners sold 2,738 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $26K.
  • LMR Partners first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • LMR Partners's Syros Pharmaceuticals, Inc. Common Stock position peaked at $26K in Q2 2022.
  • 53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on LMR Partners's 13F filing for Q3 2022, filed 14 Nov 2022.